JP2009534457A - がん治療用化合物としてのイミダゾ［４，５−ｂ］ピリジン−２−オンおよびオキサゾロ［４，５−ｂ］ピリジン−２−オン化合物およびその類似体 - Google Patents

がん治療用化合物としてのイミダゾ［４，５−ｂ］ピリジン−２−オンおよびオキサゾロ［４，５−ｂ］ピリジン−２−オン化合物およびその類似体 Download PDF

Info

Publication number
JP2009534457A
JP2009534457A JP2009507165A JP2009507165A JP2009534457A JP 2009534457 A JP2009534457 A JP 2009534457A JP 2009507165 A JP2009507165 A JP 2009507165A JP 2009507165 A JP2009507165 A JP 2009507165A JP 2009534457 A JP2009534457 A JP 2009534457A
Authority
JP
Japan
Prior art keywords
independently
alkyl
aryl
compound according
aliphatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009507165A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009534457A5 (cg-RX-API-DMAC10.html
Inventor
ニキュルスキュ−デュヴァズ，ダン
スプリンガー，キャロライン，ジョイ
マライス，リチャード，マルコム
ディクストラ，ハルメン
メナード，デルフィーン
ニキュルスキュ−デュヴァズ，イオン
デービス，ローレンス
ノーリー，アルノー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Technology Ltd
Astex Therapeutics Ltd
Original Assignee
Cancer Research Technology Ltd
Astex Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0608268.9A external-priority patent/GB0608268D0/en
Application filed by Cancer Research Technology Ltd, Astex Therapeutics Ltd filed Critical Cancer Research Technology Ltd
Publication of JP2009534457A publication Critical patent/JP2009534457A/ja
Publication of JP2009534457A5 publication Critical patent/JP2009534457A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2009507165A 2006-04-26 2007-04-26 がん治療用化合物としてのイミダゾ［４，５−ｂ］ピリジン−２−オンおよびオキサゾロ［４，５−ｂ］ピリジン−２−オン化合物およびその類似体 Pending JP2009534457A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74563306P 2006-04-26 2006-04-26
GBGB0608268.9A GB0608268D0 (en) 2006-04-26 2006-04-26 Therapeutic compounds
PCT/GB2007/001534 WO2007125330A1 (en) 2006-04-26 2007-04-26 Imidazo[4, 5-b]pyridin-2-one and oxazolo[4, 5-b]pyridin-2-one compounds and analogs thereof as cancer therapeutic compounds

Publications (2)

Publication Number Publication Date
JP2009534457A true JP2009534457A (ja) 2009-09-24
JP2009534457A5 JP2009534457A5 (cg-RX-API-DMAC10.html) 2010-06-03

Family

ID=38421488

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009507165A Pending JP2009534457A (ja) 2006-04-26 2007-04-26 がん治療用化合物としてのイミダゾ［４，５−ｂ］ピリジン−２−オンおよびオキサゾロ［４，５−ｂ］ピリジン−２−オン化合物およびその類似体

Country Status (7)

Country Link
US (1) US7951819B2 (cg-RX-API-DMAC10.html)
EP (1) EP2013207B1 (cg-RX-API-DMAC10.html)
JP (1) JP2009534457A (cg-RX-API-DMAC10.html)
AU (1) AU2007245495A1 (cg-RX-API-DMAC10.html)
CA (1) CA2649994A1 (cg-RX-API-DMAC10.html)
NO (1) NO20084688L (cg-RX-API-DMAC10.html)
WO (1) WO2007125330A1 (cg-RX-API-DMAC10.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013518089A (ja) * 2010-02-01 2013-05-20 キャンサー・リサーチ・テクノロジー・リミテッド １−（５−ｔｅｒｔ−ブチル−２−フェニル−２Ｈ−ピラゾール−３−イル）−３−［２−フルオロ−４−（１−メチル−２−オキソ−２，３−ジヒドロ−１Ｈ−イミダゾ［４，５−Ｂ］ピリジン−７−イルオキシ）−フェニル］−尿素および関連化合物ならびに治療におけるそれらの使用
JP2024526198A (ja) * 2021-06-24 2024-07-17 エルジー・ケム・リミテッド Ｒｏｎ阻害剤としての新規なウレア誘導体化合物

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110158944A1 (en) * 2007-11-30 2011-06-30 Hosted Thomas J Braf biomarkers
NZ586418A (en) 2007-12-19 2012-09-28 Cancer Rec Tech Ltd Pyrido[2,3-b]pyrazine-8-substituted compounds and their use
GB0807609D0 (en) * 2008-04-25 2008-06-04 Cancer Rec Tech Ltd Therapeutic compounds and their use
US9229008B2 (en) 2008-08-19 2016-01-05 Merck Sharp & Dohme Corp. IL-8 level as a determinant of responsivity of a cancer to treatment
WO2011021678A1 (ja) * 2009-08-21 2011-02-24 武田薬品工業株式会社 縮合複素環化合物
AU2011242697B2 (en) 2010-04-21 2015-01-22 Government Of The United States Fluoroscopy-independent, endovascular aortic occlusion system
ES2699965T3 (es) 2011-03-10 2019-02-13 Provectus Pharmatech Inc Una combinación de rosa de bengala y anticuerpo anti-CTLA4 para su uso en el tratamiento del cáncer
EP2739143B1 (en) * 2011-08-05 2018-07-11 Gary A. Flynn Preparation and methods of use for ortho-aryl 5- membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors
US9474882B2 (en) 2013-02-26 2016-10-25 Prytime Medical Devices, Inc. Fluoroscopy-independent balloon guided occlusion catheter and methods
WO2015035393A1 (en) 2013-09-09 2015-03-12 Pryor Medical Devices, Inc. Low-profile occlusion catheter
GB201320732D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Methods of chemical synthesis
GB201320729D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
US10232142B2 (en) 2014-06-10 2019-03-19 Prytime Medical Devices, Inc. Conduit guiding tip
AU2016232781B2 (en) 2015-03-19 2017-11-02 Prytime Medical Devices, Inc. System for low-profile occlusion balloon catheter
CA2990479C (en) 2016-06-02 2019-03-26 Prytime Medical Devices, Inc. System and method for low-profile occlusion balloon catheter
AU2017312970B2 (en) 2016-08-16 2021-08-12 Merck Patent Gmbh 2-oxo-imidazopyridines as reversible BTK inhibitors and uses thereof
WO2018132623A1 (en) 2017-01-12 2018-07-19 The Regents Of The University Of California Endovascular perfusion augmentation for critical care
CN117105827A (zh) 2017-03-27 2023-11-24 魁北克电力公司 用于电解质组合物中或用作电极添加剂的盐
CA3060519A1 (en) 2017-04-21 2018-10-25 The Regents Of The University Of California Aortic flow meter and pump for partial-aortic occlusion
CN118903436A (zh) 2018-01-31 2024-11-08 德西费拉制药有限责任公司 治疗肥大细胞增多症的组合疗法
KR102708177B1 (ko) 2018-01-31 2024-09-23 데시페라 파마슈티칼스, 엘엘씨. 위장관 기질 종양의 치료를 위한 병용 요법
WO2020033372A1 (en) 2018-08-06 2020-02-13 Prytime Medical Devices, Inc. System and method for low profile occlusion balloon catheter
IL330104A (en) 2019-03-11 2026-08-01 Deciphera Pharmaceuticals Llc Crystalline forms of rifatinib
PL4010330T3 (pl) 2019-08-08 2026-03-16 Hirundo Biosciences Pochodne chinoliny jako inhibitory kinazy białkowej
US12691108B2 (en) 2019-08-12 2026-07-28 Deciphera Pharmaceuticals, Llc Methods for treating vascular malformations
HRP20260411T1 (hr) 2019-08-12 2026-05-08 Deciphera Pharmaceuticals, Llc Ripretinib za liječenje gastrointestinalnih stromalnih tumora
WO2021057696A1 (zh) * 2019-09-27 2021-04-01 隆泰申医药科技(南京)有限公司 一种杂芳基类化合物及其应用
FI4084779T3 (fi) 2019-12-30 2024-12-16 Deciphera Pharmaceuticals Llc 1-(4-bromi-5-(1-etyyli-7-(metyyliamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yyli)-2-fluorifenyyli)-3-fenyyliurean koostumuksia
WO2021188602A2 (en) 2020-03-16 2021-09-23 Certus Critical Care, Inc. Blood flow control devices, systems, and methods and error detection thereof
US11629143B2 (en) 2020-10-01 2023-04-18 Vibliome Therapeutics, Llc HipK4 inhibitors and uses thereof
US12102330B2 (en) 2021-03-18 2024-10-01 Prytime Medical Devices, Inc. Vascular occlusion catheter for partial occlusion or full occlusion
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors
CN120239701A (zh) 2022-11-24 2025-07-01 Bci制药公司 作为蛋白激酶抑制剂的吡啶衍生物
EP4750767A1 (en) 2023-07-26 2026-06-03 Hirundo Biosciences Quinazolinone, benzoxazinone and benzoxazepinone derivatives as protein kinase inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001046196A1 (en) * 1999-12-21 2001-06-28 Sugen, Inc. 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors
US20040082583A1 (en) * 2000-11-29 2004-04-29 Mui Cheung Chemical compounds
WO2006024834A1 (en) * 2004-08-31 2006-03-09 Astrazeneca Ab Quinazolinone derivatives and their use as b-raf inhibitors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5665863A (en) 1979-10-31 1981-06-03 Tokyo Organ Chem Ind Ltd Novel aniline derivative, its preparation and pesticide containing the same
JPS5738777A (en) 1980-08-19 1982-03-03 Sogo Yatsukou Kk 2-sufanilamidopyrathyn derivative
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5879672A (en) 1994-10-07 1999-03-09 Regeneron Pharmaceuticals, Inc. Tie-2 ligand 1
US5643755A (en) 1994-10-07 1997-07-01 Regeneron Pharmaceuticals Inc. Nucleic acid encoding tie-2 ligand
EP0783572B1 (en) 1994-09-22 2005-04-27 Licentia Ltd. Promoter for the receptor tyrosine kinase, tie
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
ZA971896B (en) 1996-03-26 1998-09-07 Du Pont Merck Pharma Aryloxy-and arythio-fused pyridines and pyrimidines and derivatives
CA2744096C (en) 1996-07-31 2013-07-30 Laboratory Corporation Of America Holdings Biomarkers and targets for diagnosis, prognosis and management of prostate disease
US6030831A (en) 1997-09-19 2000-02-29 Genetech, Inc. Tie ligand homologues
RU2230553C2 (ru) 1997-09-26 2004-06-20 Центарис АГ Способ модулирования функции серин/треонин протеинкиназы соединением на основе азабензимидазола, способ идентификации соединений, модулирующих функцию серин/треонин протеинкиназы, способ профилактики или лечения патологических состояний в организме, соединение на основе азабензимидазола, способ его синтеза и фармацевтическая композиция
GB9721437D0 (en) 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
GB2356398A (en) 1999-11-18 2001-05-23 Lilly Dev Ct S A Preparation of arylsulfamides
US6492529B1 (en) 2000-01-18 2002-12-10 Boehringer Ingelheim Pharmaceuticals, Inc. Bis pyrazole-1H-pyrazole intermediates and their synthesis
EP1456364B1 (en) 2001-12-21 2011-03-23 The Wellcome Trust Mutations in the b-raf gene
JP4335136B2 (ja) 2002-08-09 2009-09-30 メルク エンド カムパニー インコーポレーテッド チロシンキナーゼ阻害薬
TW200616974A (en) 2004-07-01 2006-06-01 Astrazeneca Ab Chemical compounds
GB0423554D0 (en) 2004-10-22 2004-11-24 Cancer Rec Tech Ltd Therapeutic compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001046196A1 (en) * 1999-12-21 2001-06-28 Sugen, Inc. 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors
US20040082583A1 (en) * 2000-11-29 2004-04-29 Mui Cheung Chemical compounds
WO2006024834A1 (en) * 2004-08-31 2006-03-09 Astrazeneca Ab Quinazolinone derivatives and their use as b-raf inhibitors

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013518089A (ja) * 2010-02-01 2013-05-20 キャンサー・リサーチ・テクノロジー・リミテッド １−（５−ｔｅｒｔ−ブチル−２−フェニル−２Ｈ−ピラゾール−３−イル）−３−［２−フルオロ−４−（１−メチル−２−オキソ−２，３−ジヒドロ−１Ｈ−イミダゾ［４，５−Ｂ］ピリジン−７−イルオキシ）−フェニル］−尿素および関連化合物ならびに治療におけるそれらの使用
JP2015180675A (ja) * 2010-02-01 2015-10-15 キャンサー・リサーチ・テクノロジー・リミテッド １−（５−ｔｅｒｔ−ブチル−２−フェニル−２Ｈ−ピラゾール−３−イル）−３−［２−フルオロ−４−（１−メチル−２−オキソ−２，３−ジヒドロ−１Ｈ−イミダゾ［４，５−Ｂ］ピリジン−７−イルオキシ）−フェニル］−尿素および関連化合物ならびに治療におけるそれらの使用
JP2024526198A (ja) * 2021-06-24 2024-07-17 エルジー・ケム・リミテッド Ｒｏｎ阻害剤としての新規なウレア誘導体化合物
JP2024526197A (ja) * 2021-06-24 2024-07-17 エルジー・ケム・リミテッド Ｒｏｎ阻害剤としての新規なウレア誘導体化合物

Also Published As

Publication number Publication date
CA2649994A1 (en) 2007-11-08
NO20084688L (no) 2009-01-26
US20090325945A1 (en) 2009-12-31
AU2007245495A1 (en) 2007-11-08
US7951819B2 (en) 2011-05-31
WO2007125330A1 (en) 2007-11-08
EP2013207B1 (en) 2012-04-25
EP2013207A1 (en) 2009-01-14

Similar Documents

Publication Publication Date Title
JP4926973B2 (ja) 治療化合物としての、イミダゾ［４，５−ｂ］ピリジン−２−オンおよびオキサゾロ［４，５−ｂ］ピリジン−２−オン化合物ならびにそれらの類似体
EP2013207B1 (en) Imidazo[4,5-b]pyridin-2-one compounds and analogs thereof as cancer therapeutic compounds
JP5511680B2 (ja) ピリド［２，３−ｂ］ピラジン−８−置換化合物及びその使用
JP2008525409A (ja) 治療用化合物としてのピラジンおよびピリジンならびにその誘導体
JP7256757B2 (ja) 処置用化合物及び組成物、並びにその使用方法
JP2011518819A (ja) アリール−キノリル化合物及びその使用
ES2385103T3 (es) Compuestos de imidazo[4,5-b]piridin-2-ona y análogos de los mismos como compuestos terapéuticos contra el cáncer
HK1100368B (en) Imidazo[4,5-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-one compounds and analogs thereof as therapeutic compounds
HK1148521B (en) Pyrido[2,3-b]pyrazine-8-substituted compounds and their use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20090610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100419

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100419

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120821

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20120821

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120830

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120906

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130507